Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Sell
36
PMN Quote, Financials, Valuation and Earnings
Last price:
$8.21
Seasonality move
:
3.03%
Day range:
$8.13 - $8.52
52-week range:
$6.27 - $39.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.90x
Volume:
4.9K
Avg. volume:
29.4K
1-year change:
-68.12%
Market cap:
$17.5M
Revenue:
--
EPS (TTM):
-$13.58
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PMN
ProMIS Neurosciences, Inc.
|
-- | -- | -- | -- | $105.58 |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$74.7M | $0.22 | 24.77% | 2133.71% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $11.00 |
|
LEXX
Lexaria Bioscience Corp.
|
$100K | -- | -42.53% | -- | $4.50 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.05 | -- | -10.97% | $5.50 |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-- | -$1.13 | -100% | -36.71% | $55.51 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PMN
ProMIS Neurosciences, Inc.
|
$8.13 | $105.58 | $17.5M | -- | $0.00 | 0% | -- |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$15.15 | $16.67 | $2B | 27.00x | $0.00 | 0% | 8.04x |
|
EDSA
Edesa Biotech, Inc.
|
$1.50 | $11.00 | $10.5M | -- | $0.00 | 0% | 31.22x |
|
LEXX
Lexaria Bioscience Corp.
|
$0.75 | $4.50 | $18.6M | -- | $0.00 | 0% | 19.03x |
|
ONCY
Oncolytics Biotech, Inc.
|
$0.97 | $5.50 | $104.1M | -- | $0.00 | 0% | -- |
|
XENE
Xenon Pharmaceuticals, Inc.
|
$42.15 | $55.51 | $3.3B | -- | $0.00 | 0% | 442.96x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PMN
ProMIS Neurosciences, Inc.
|
-- | 0.079 | -- | 1.26x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | -0.204 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -1.109 | -- | 10.60x |
|
LEXX
Lexaria Bioscience Corp.
|
2.06% | -0.522 | 0.6% | 3.11x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.553 | 0.41% | 1.61x |
|
XENE
Xenon Pharmaceuticals, Inc.
|
1.47% | -0.090 | 0.27% | 12.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PMN
ProMIS Neurosciences, Inc.
|
-- | -$11.8M | -348.3% | -348.3% | -- | -$10.2M |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.9K | -$2.5M | -77.45% | -77.48% | -- | -$1.8M |
|
LEXX
Lexaria Bioscience Corp.
|
$152.6K | -$2.5M | -144.76% | -147.19% | -2155.4% | -$3.6M |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-$641K | -$96.3M | -43.83% | -44.39% | -969.84% | -$72.7M |
ProMIS Neurosciences, Inc. vs. Competitors
-
Which has Higher Returns PMN or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -- compared to ProMIS Neurosciences, Inc.'s net margin of 42.95%. ProMIS Neurosciences, Inc.'s return on equity of -348.3% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital PMNProMIS Neurosciences, Inc.-- -$5.93 $9.2M AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About PMN or AUPH?
ProMIS Neurosciences, Inc. has a consensus price target of $105.58, signalling upside risk potential of 1198.67%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 10.01%. Given that ProMIS Neurosciences, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe ProMIS Neurosciences, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMNProMIS Neurosciences, Inc.2 0 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is PMN or AUPH More Risky?
ProMIS Neurosciences, Inc. has a beta of -0.097, which suggesting that the stock is 109.676% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.462, suggesting its more volatile than the S&P 500 by 46.187%.
-
Which is a Better Dividend Stock PMN or AUPH?
ProMIS Neurosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProMIS Neurosciences, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMN or AUPH?
ProMIS Neurosciences, Inc. quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. ProMIS Neurosciences, Inc.'s net income of -$11.6M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, ProMIS Neurosciences, Inc.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 27.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProMIS Neurosciences, Inc. is -- versus 8.04x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMNProMIS Neurosciences, Inc.-- -- -- -$11.6M AUPHAurinia Pharmaceuticals, Inc.8.04x 27.00x $73.5M $31.6M
-
Which has Higher Returns PMN or EDSA?
Edesa Biotech, Inc. has a net margin of -- compared to ProMIS Neurosciences, Inc.'s net margin of --. ProMIS Neurosciences, Inc.'s return on equity of -348.3% beat Edesa Biotech, Inc.'s return on equity of -77.48%.
Company Gross Margin Earnings Per Share Invested Capital PMNProMIS Neurosciences, Inc.-- -$5.93 $9.2M EDSAEdesa Biotech, Inc.-- -$0.32 $12.5M -
What do Analysts Say About PMN or EDSA?
ProMIS Neurosciences, Inc. has a consensus price target of $105.58, signalling upside risk potential of 1198.67%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 633.33%. Given that ProMIS Neurosciences, Inc. has higher upside potential than Edesa Biotech, Inc., analysts believe ProMIS Neurosciences, Inc. is more attractive than Edesa Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMNProMIS Neurosciences, Inc.2 0 0 EDSAEdesa Biotech, Inc.2 0 0 -
Is PMN or EDSA More Risky?
ProMIS Neurosciences, Inc. has a beta of -0.097, which suggesting that the stock is 109.676% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.133, suggesting its less volatile than the S&P 500 by 86.677%.
-
Which is a Better Dividend Stock PMN or EDSA?
ProMIS Neurosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProMIS Neurosciences, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMN or EDSA?
ProMIS Neurosciences, Inc. quarterly revenues are --, which are smaller than Edesa Biotech, Inc. quarterly revenues of --. ProMIS Neurosciences, Inc.'s net income of -$11.6M is lower than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, ProMIS Neurosciences, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProMIS Neurosciences, Inc. is -- versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMNProMIS Neurosciences, Inc.-- -- -- -$11.6M EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M
-
Which has Higher Returns PMN or LEXX?
Lexaria Bioscience Corp. has a net margin of -- compared to ProMIS Neurosciences, Inc.'s net margin of -2178.51%. ProMIS Neurosciences, Inc.'s return on equity of -348.3% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.
Company Gross Margin Earnings Per Share Invested Capital PMNProMIS Neurosciences, Inc.-- -$5.93 $9.2M LEXXLexaria Bioscience Corp.91.15% -$0.14 $5.3M -
What do Analysts Say About PMN or LEXX?
ProMIS Neurosciences, Inc. has a consensus price target of $105.58, signalling upside risk potential of 1198.67%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $4.50 which suggests that it could grow by 503.22%. Given that ProMIS Neurosciences, Inc. has higher upside potential than Lexaria Bioscience Corp., analysts believe ProMIS Neurosciences, Inc. is more attractive than Lexaria Bioscience Corp..
Company Buy Ratings Hold Ratings Sell Ratings PMNProMIS Neurosciences, Inc.2 0 0 LEXXLexaria Bioscience Corp.1 0 0 -
Is PMN or LEXX More Risky?
ProMIS Neurosciences, Inc. has a beta of -0.097, which suggesting that the stock is 109.676% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.631, suggesting its less volatile than the S&P 500 by 36.888%.
-
Which is a Better Dividend Stock PMN or LEXX?
ProMIS Neurosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProMIS Neurosciences, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMN or LEXX?
ProMIS Neurosciences, Inc. quarterly revenues are --, which are smaller than Lexaria Bioscience Corp. quarterly revenues of $174K. ProMIS Neurosciences, Inc.'s net income of -$11.6M is lower than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, ProMIS Neurosciences, Inc.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProMIS Neurosciences, Inc. is -- versus 19.03x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMNProMIS Neurosciences, Inc.-- -- -- -$11.6M LEXXLexaria Bioscience Corp.19.03x -- $174K -$2.7M
-
Which has Higher Returns PMN or ONCY?
Oncolytics Biotech, Inc. has a net margin of -- compared to ProMIS Neurosciences, Inc.'s net margin of --. ProMIS Neurosciences, Inc.'s return on equity of -348.3% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital PMNProMIS Neurosciences, Inc.-- -$5.93 $9.2M ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About PMN or ONCY?
ProMIS Neurosciences, Inc. has a consensus price target of $105.58, signalling upside risk potential of 1198.67%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 470.11%. Given that ProMIS Neurosciences, Inc. has higher upside potential than Oncolytics Biotech, Inc., analysts believe ProMIS Neurosciences, Inc. is more attractive than Oncolytics Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMNProMIS Neurosciences, Inc.2 0 0 ONCYOncolytics Biotech, Inc.4 1 0 -
Is PMN or ONCY More Risky?
ProMIS Neurosciences, Inc. has a beta of -0.097, which suggesting that the stock is 109.676% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.717%.
-
Which is a Better Dividend Stock PMN or ONCY?
ProMIS Neurosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProMIS Neurosciences, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMN or ONCY?
ProMIS Neurosciences, Inc. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. ProMIS Neurosciences, Inc.'s net income of -$11.6M is lower than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, ProMIS Neurosciences, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProMIS Neurosciences, Inc. is -- versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMNProMIS Neurosciences, Inc.-- -- -- -$11.6M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns PMN or XENE?
Xenon Pharmaceuticals, Inc. has a net margin of -- compared to ProMIS Neurosciences, Inc.'s net margin of -867.29%. ProMIS Neurosciences, Inc.'s return on equity of -348.3% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.
Company Gross Margin Earnings Per Share Invested Capital PMNProMIS Neurosciences, Inc.-- -$5.93 $9.2M XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M -
What do Analysts Say About PMN or XENE?
ProMIS Neurosciences, Inc. has a consensus price target of $105.58, signalling upside risk potential of 1198.67%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.51 which suggests that it could grow by 31.69%. Given that ProMIS Neurosciences, Inc. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe ProMIS Neurosciences, Inc. is more attractive than Xenon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMNProMIS Neurosciences, Inc.2 0 0 XENEXenon Pharmaceuticals, Inc.17 0 0 -
Is PMN or XENE More Risky?
ProMIS Neurosciences, Inc. has a beta of -0.097, which suggesting that the stock is 109.676% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 0.974, suggesting its less volatile than the S&P 500 by 2.579%.
-
Which is a Better Dividend Stock PMN or XENE?
ProMIS Neurosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProMIS Neurosciences, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMN or XENE?
ProMIS Neurosciences, Inc. quarterly revenues are --, which are smaller than Xenon Pharmaceuticals, Inc. quarterly revenues of --. ProMIS Neurosciences, Inc.'s net income of -$11.6M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, ProMIS Neurosciences, Inc.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProMIS Neurosciences, Inc. is -- versus 442.96x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMNProMIS Neurosciences, Inc.-- -- -- -$11.6M XENEXenon Pharmaceuticals, Inc.442.96x -- -- -$90.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
